“We are excited to share our modeling analysis on the Cost of Goods for the manufacturing of Molnupiravir, a critical, life-saving COVID-19 therapeutic. The paper is a result of collaboration between multiple organizations and LBG team members, and the conclusions identify multiple, alternative manufacturing methodologies, which can result in cost reductions through synthesis optimization.” – Chris Peterson, Sia/LBG
Read the full article here.